Therapy in Focus
INSIGHTEC is the global leader in the technology of MR-guided-Focused Ultrasound (MRgFUS). The company develops and distributes an MRgFUS therapy platform, Exablate, that is transforming medicine by providing a non-invasive therapeutic alternative to millions of potential patients around the world.
INSIGHTEC’s Exablate platform is used to treat indications in Women’s Health, Oncology and Neurosurgery. MRgFUS technology was developed over a decade ago and it has been proven safe and effective through numerous clinical trials. The Exablate system has received FDA Approval for treating symptomatic uterine fibroids, pain palliation of bone metastases and treatment of Essential Tremor. The technology has been embraced by leading physicians around the world.
Ablation of uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure and whose uterine size is less than 24 weeks.
The Exablate Neuro is intended for use in the unilateral Thalamotomy treatment of idiopathic Essential Tremor patients with medication-refractory tremor. Patients must be at least age 22.
Pain palliation of metastatic bone cancer in patients 18 years of age or older who are suffering from bone pain due to metastatic diseases and who are failures of standard radiation therapy, or not candidates for, or refused radiation therapy. The bone tumor to be treated must be visible on a non-contrast MR and device accessible.